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Abstract: In recent years, the popularity increased for nutritional supplements and herbal products. Prescription drugs, but not 
herbal therapies are paid by health insurances. They are sold over-the-counter (OTC) on the patients’ own expense. However, there 
are potential risks of self-medication, e.g. incorrect self-diagnosis, severe adverse reactions, dangerous drug interactions, risk of 
addiction etc. They are often used by patients at their own discretion without knowledge of and control by their physicians. Certain 
users are at risk of intoxication. Multiple medications taken by older patients increase the risk for adverse drug reactions, drug-drug 
interactions, and compliance problems for this age group (polypharmacy). Herbals should be discontinued prior to operations to 
avoid interactions with anesthetics or anticoagulants. Herbal preparations may also be carcinogenic or interfere with cancer treat-
ments. Pregnant women use various OTC preparations. However, in many cases, it is unclear whether their use is safe for mother or 
baby. Self-medication with herbals is also largely distributed among anxious and depressive patients, and patients with other condi-
tions and symptoms. The popularity of herbal products has also brought concerns on quality, efficacy and safety. Cases of botanical 
misidentification, contaminations with heavy metals, pesticides, radioactivity, organic solvents, microbials as well as adulteration 
with chemical drugs necessitate the establishment of international quality control standards. Hepatotoxic effects have been reported 
for more than 300 plant species, and some commonly used herbs have been demonstrated to interact with Western medication. 
Health care professionals have a critical responsibility assessing the self-care ability of their patients. Databases are available for 
pharmacists with information on action, side effects and toxicities as well as herb-drug interactions. There is a need for established 
guidelines regarding the correct use of nutritional supplements and herbal OTC preparations (phytovigilance). Physicians, pharma-
cists, and other health care professionals have to counsel patients and the general public on the benefits and risks associated with 
herbal drugs. Information centers for consumers and general practitioners are needed, and convincing evidence on safety and effica-
cy of herbal products has to be demonstrated in placebo-controlled, double blind and randomized clinical trials. 
Keywords: botanicals, contamination, complementary and alternative medicine, drug interactions, geriatric, gynecology, insomnia, 
hepatotoxicity, menopause, nephrotoxicity, over-the-counter, pain, phase I/II enzymes, pharmacognosy, pharmacovigilance, phyto-
chemicals, phytotherapy, phytovigilance, quality control
Introduction 
According to estimations of the World Health Organisation, 
70-80% of the world populations rely on non-conventional 
medicine mainly of herbal sources in their primary health 
care.1,2 While patients in developing countries depend on 
herbal medicine because they cannot afford the costs for 
prescription Western medicine, the situation is vice versa in 
industrialized countries. In recent years, the popularity 
increased for over-the-counter (OTC) health foods, 
nutraceuticals, and medicinal products from plants or other 
natural sources in industrialized countries. Prescription drugs 
but not herbal therapies are paid by the health insurance 
system. They are sold over-the-counter on the own expense of 
the patients. Therefore, herbal OTC products and 
complementary and alternative medicine (CAM) attracts 
patients from higher social classes. This also indirectly 
indicates that the public might not be satisfied with their 
Western medical treatment.3 
If herbal medicines meet rigourous quality control in 
production and evidence-based standards in safety and 
efficacy, they would have the potential to reduce costs for the 
health insurance systems. The frequent reluctance of the 
pharmaceutical industry is understandable in terms of the 
difficult patent situation with phytotherapy and the 
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possibilities to earn money with herbal products and 
nutritional supplements. However, faced with ever-increasing 
costs for medications, phytotherapy bears a considerable 
potential for future health care in times of bursting in health 
systems. As compared to conventional patients, CAM patients 
cause lower costs.4 
Self-medication is defined as the use of medicines to treat 
self-recognized conditions or symptoms. One benefit of self-
medication may be the active role of the patient in his/her own 
health care. However, there are potential risks of self-
medication, e.g. incorrect self-diagnosis, delays in seeking 
medical advice when needed, severe adverse reactions, 
dangerous drug interactions, masking of a severe disease, risk 
of addiction, and abuse.5 
Herbs are classified as dietary supplements (not drugs), and 
manufacturers are therefore not required to provide proof of 
efficacy or safety before selling these substances. The general 
community perception that herbal preparations are safe may 
lead to inappropriate use. Improper intake may causer 
unwanted side effects and toxicities both in industrialized and 
developing countries.6,7 
CAM is actually a vast collection of disparate, unrelated 
therapies and products, ranging from treatment modalities that 
effectively enhance quality of life to promising herbal 
remedies.8 Complementary therapies such as music and 
massage, herbal teas, yoga, tai chi, meditation, and many other 
techniques that augment Western medical treatment. A lack of 
regulations leaves consumers at the mercy of those who 
promote unproved remedies. Herb-drug interactions frequently 
require that patients stop taking herbal remedies prior to 
surgery (to prevent interactions with anesthetics and 
anticoagulant effects), radiation (due to potential for increased 
radiosensitivity of healthy tissues), and chemotherapy (to 
prevent herb-drug interactions). 
Although laws pertaining to dietary supplement labeling 
prohibit specific claims for the treatment or prevention of 
disease, these products are widely used as CAM therapies. 
Complex issues persist, which have to be addressed when 
consulting patients.9 
Dietary supplements are often used by patients at their own 
discretion without knowledge of and control by their 
physicians. Patients may anticipate physicians' disapproval of 
their use, or not realize that it is important for the physician to 
know what they are taking. Therefore, it is imperative that 
patients are asked unbiassed questions about current and past 
use of herbals and alternative therapies. Even when physicians 
are aware of such use, they feel poorly trained to identify the 
constituents and effects.10 
There is still limited evidence to evaluate the efficacy of the 
approximately 20,000 available herbal products. Because 
herbs contain potent bioactive substances and are often 
marketed to treat specific diseases, many have argued that they 
should be subject to more stringent regulations.11 To improve 
the safety and consistency of herbs, additional research is 
needed to define the pharmacology, stability, and 
bioavailability of these products. Approaches for regulation 
and common-sense guidelines are necessary. 
 
1 Target Groups of Self-Medication 
In principle, self-medication can be applied by the general 
public. However, certain users of herbs are at high risk of 
intoxication.12 These include chronic users consuming large 
amounts or a great variety, malnourished or undernourished 
persons and patients on long term medication. Certain plant 
toxins may be gender-selective in their action. Here, we focus 
on groups of patients, which frequently take nutritional 
supplements and herbal OTC products to treat their ailments, 




Since older adults are a growing sector of the population in 
many countries, it is important to know the prevalence of their 
herbal product use. To estimate the prevalence of self-
medication in the elderly, Vacas Rodilla et al.13 performed a 
cross-sectional descriptive study. A total of 240 patients 75 
years of age or older have been assessed in an urban primary 
health care centre in Spain. Self-medication frequency was 
31%, with 23% being pharmacological and 15% herbal. The 
drugs most used in self-medication were analgesics and cold 
remedies. The pharmacy was the most usual source (49%). 
Accumulating drugs in homes was a very extensive practice. 
The plethora of medications taken by older patients 
increases the risk for adverse drug reactions, drug-drug 
interactions, and non-compliance for this age group. This 
situation has been termed polypharmacy, which is defined as 
the use of (too) many different medications, which increases 
the probability of side effects and drug interactions. As 
pointed out by Tam-McDevitt,14 polypharmacy can be an issue 
in any age group, but seems to be especially a problem for the 
elderly, who consume more medications than any other patient 
group. Factors such as the presence of multiple co-morbid 
conditions, advances in pharmacotherapy, and increased 
availability of OTC and herbal supplements for self-treatment 
can all contribute to polypharmacy in this population. 
Physiologic changes associated with aging may alter the 
pharmacokinetic and pharmacodynamics of drug metabolism, 
which in turn affects potential drug toxicities.  
It is important to avoid health complications due to the 
concomitant use of diverse medications and herbs. González-
Stuart15 reported that elderly are especially vulnerable, since 
the human body's physiological activities, such as renal and 
hepatic detoxification and clearance usually decrease with age. 
Elderly taking combinations of various medications and herbal 
supplements are also more at risk to experience herb-drug 
interactions. 
Musculoskeletal pain in the elderly is common and 
disabling. As the conditions causing rheumatic pain, including 
osteoarthritis, inflammatory arthritis and certain soft-tissue 
conditions are mostly not curable, pain control is paramount to 
maintain quality of life. Pain management is multimodal and 
tailored to the individual patient. Although herbal products and 
nutritional supplements are commonly used by patients, 
studies of their efficacy and safety, especially in the elderly, 
are limited.16 The use of any pharmacological agent in the 
elderly - being it standard pharmacology or herbal remedy - 
should be tempered with caution regarding increased 
sensitivity to medications, herbal-drug interactions and 
associated co-morbidities. Therefore, the elderly will often 
require down-adjustment of dosage and careful attention to the 
risk/benefit ratio of the treatment. However, barriers to 
effective pain management from the perspective of both the 
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patient and the healthcare professional still exist, and have to 
be overcome by educational efforts. 
Results from clinical trials demonstrate that standardized 
leaf extracts of Ginkgo biloba reduce the symptoms of age-
associated memory impairment and dementia, including 
Alzheimer's disease, and may be of benefit in treating 
intermittent claudication.17 In addition, Ginkgo biloba extract 
may be useful in preventing and treating cardiovascular 
disease (CVD), particularly ischemic cardiac syndrome.18 
Several herbal or alternative therapeutics can significantly 
elevate blood pressure or cause interactions with 
cardiovascular drugs. Vora and Mansoor10 reviewed the 
epidemiology of alternative therapy use, and selected several 
important herbal or other supplements that patients with 
hypertension and cardiovascular diseases may be taking. 
 
Surgical Patients 
The American Society of Anesthesiologists (ASA) 
recommends that all herbal medications should be 
discontinued two to three weeks prior to an elective surgical 
procedure.19 King and colleagues20 performed a retrospective 
review of surgery patients presenting to the Anesthesia 
Preoperative Evaluation Clinic (APEC) at the University of 
Kansas Hospital (Kansas City, KS, U.S.A.). Approximately 
one-fourth of patients indicated the use of natural products. 
Patients taking natural products were significantly older, were 
more likely to undergo cardiac or chest surgery, and were 
more likely to take more prescription and non-prescription 
medications. 
At the University of Colorado Health Sciences Center 
(Denver, Colorado, USA) Norred et al.21 surveyed 500 elective 
surgical outpatients about alternative medicines taken during 
the two weeks prior to surgery. Of 500 patients surveyed, 51% 
preoperatively took herbs, vitamins, dietary supplements, or 
homeopathic medicines. Two or more categories of alternative 
medicines (herbs, vitamins, dietary supplements, or 
homeopathic medicines) were consumed by 24% of patients. 
Twenty-four percent of surveyed patients consumed 50 
different herbs, 41% took 9 types of vitamins, 44% took 31 
types of dietary supplements, and 1% of patients took 
homeopathic Arnica. Classification by potential adverse 
effects revealed that 27% of surgical patients consumed 
alternative medicines that may inhibit coagulation, affect 
blood pressure, cause sedation, have cardiac effects, or alter 
electrolytes. 
Rowe and Baker22 reviewed research on the possible 
benefits and risks of commonly used herbal medications such 
as Arnica montana, St. John's wort, bromelain, Echinacea, 
Ginkgo biloba, Ephedra, valerian, and others, focusing on 
their potential impact during the perioperative period of 
aesthetic surgery. A large percentage of patients undergoing 
plastic surgery use one or more herbal medications, but the 
disclosure of such medications to allopathic providers is often 
incomplete. In addition, patients may not understand the 
importance of discontinuing such medications before surgery. 
Dental professionals routinely treat patients taking 
prescription, nonprescription, and herbal medications that are 
known or have the potential to alter bleeding. Herbal 
supplements are widely used for a variety of indications, and 
both patients and health care practitioners are often unaware of 
the potential consequences. Decision-making strategies, such 
as interpretation of laboratory tests etc. should be applied. 
Herbal supplements must be discontinued two weeks prior to 
receiving invasive dental surgical procedures. Dental 
practitioners should implement risk reduction strategies to 
minimize adverse bleeding complications associated with 
dental treatment.23 
 
Patients with Tumors or Benign Hyperplasias 
Herbs and natural products may also be carcinogenic or 
interfere with cancer treatments. Some herbs may have 
estrogenic effects and compete with hormone cancer therapies, 
whereas others interfere with chemotherapy treatment or may 
induce recurrence of cancer.24 Between 7% and 48% of cancer 
patients take herbal medicines after diagnosis.25 Despite 
known interactions with conventional cancer treatments and 
contraindications for some herbal remedies with specific 
cancers, reliable information resources for patients are very 
limited. Identifying cancer patients' information needs and 
preferences is the first step in creating a suitable resource for 
both the public and professionals advising them. 
PC-SPES is a potent eight-herb formulation sold directly to 
consumers. It has promising efficacy in the treatment of 
prostate cancer. The product induces a castrate status, resulting 
in a 50% or greater prostate-specific antigen reduction in the 
majority of men with androgen-dependent prostate carcinoma 
and in more than one half of the men with androgen-
independent prostate cancer.26 The duration of response is not 
yet clear. The efficacy of PC-SPES appears to exceed that of 
androgen ablation alone, but is not necessarily separate from 
an estrogenic effect. Common side effects include 
gynecomastia, nipple tenderness, loss of libido, and impotency. 
The mechanisms of action may involve down-regulation of the 
androgen receptor, induction of apoptosis and increased 
expression of p53. Two bioactive compounds in PC-SPES are 
baicalin and oridonin. FDA has warned consumers to stop 
taking the dietary supplement/herbal product PC-SPES 
because they contain undeclared prescription drug ingredients 
that could cause serious health effects if not taken under 
medical supervision. In February 2002, the manufacturer of 
the product in U.S.A. voluntarily recalled PC-SPES 
nationwide.27 
Phytotherapeutic agents have also gained widespread use in 
the treatment of benign prostatic hyperplasia and lower urinary 
tract symptoms. Although numerous mechanisms of action 
have been postulated, it is still uncertain which are responsible 




Pregnant women use a range of OTC preparations, 
including analgesics, antihistamines, antacids and a variety of 
herbal preparations.29 However, in many cases, it is unclear 
whether their use is actually safe in the short- or long-term for 
mother or baby.  Few studies about effects of herbs have been 
conducted in the general population, and fewer still have been 
published about certain risk groups. Because the perinatal 
nurse has two patients to consider when caring for a pregnant 
woman, he or she has two equally important mandates: to help 
the mother without harming the fetus.30 
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Tiran31 and Holst et al.32 reported on safety and efficacy of 
the most commonly used herbs to enable midwives to give 
evidence-based information to pregnant women. A total of 578 
expectant mothers at least 20-weeks pregnant were surveyed. 
Fifty-eight percent of the participants used one or more herbal 
remedies. The most commonly used herbal preparations during 
pregnancy were ginger, cranberry, raspberry leaf, chamomile, 
peppermint and Echinacea. Although 14 studies focusing on 
the safety and/or efficacy of these herbals in human pregnancy 
were identified, the authors felt that there is limited 
documentation on the safety and efficacy of many herbs 
commonly used during pregnancy. 
Dugoua et al.33 focused on the use, safety and pharmacology 
of blue cohosh during pregnancy and lactation in U.S.A.. 
Approximately 64% of midwives use blue cohosh as a labour-
inducing aid.  Blue cohosh taken at the time of delivery may 
cause (1) perinatal stroke, (2) acute myocardial infarction, 
profound congestive heart failure and shock (3) severe multi-
organ hypoxic injury, and (4) in rare cases blue cohosh 
possesses abortifacient properties. There is in vitro evidence 
that blue cohosh may have teratogenic, embryotoxic and 
oxytoxic effects. In lactation, the safety of blue cohosh is 
unknown. Based on the available scientific information, blue 
cohosh should (1) be used with extreme caution during 
pregnancy, (2) be used only under medical professional 
supervision, and (3) not be available to the public as an OTC 
product. There is an urgent need to conduct retrospective or 
prospective cohort studies of midwifes using blue cohosh to 
determine its safety.  
 
Slimming Persons 
OTC dietary supplements to treat obesity appeal many 
patients for weight loss. Non-prescription products available to 
control weight include herbal dietary supplements.34,35 The 
introduction of orlistat as OTC product represents the only 
Food and Drug Administration (FDA)-approved product for 
weight loss currently in that category, since phenylpropanol-
amine (PPA) was withdrawn by FDA.  
Although evidence of modest weight loss after Ephedra-
caffeine ingestion exists, potentially serious adverse effects 
have led FDA to ban the sale of these products. Guar gum and 
chitosan appear to be ineffective. Because of insufficient or 
conflicting evidence regarding the efficacy of conjugated 
linoleic acid, ginseng, glucomannan, green tea, hydroxycitric 
acid, L-carnitine, psyllium, and St. John's wort in weight loss, 




Conventional treatment for primary dysmenorrhoea (painful 
menstruation) has a failure rate of 20% to 25%. Chinese herbal 
medicine may be a suitable alternative treatment. Zhu et al.37 
selected and evaluated 39 randomised controlled trials with a 
total of 3475 women involving Chinese herbal medicine 
versus placebo, no treatment, conventional therapy, heat 
compression, acupuncture or massage. Chinese herbal 
medicine resulted in significant improvements in pain relief, 
overall symptoms when compared to standard drugs. Chinese 
herbal medicine also resulted in better pain relief than 
acupuncture and heat compression. Although the review found 
promising evidence supporting the use of Chinese herbal 
medicine for primary dysmenorrhoea, the results were limited 
by the poor methodological quality of the included trials. 
 
Menopausal Women 
Postmenopausal women frequently use OTC therapies for 
the treatment of hot flashes. Herbal remedies include black 
cohosh, isoflavones, red clover, soy, vitamin E, ginseng, 
evening primrose oil, wild yam, kava, melatonin and others. A 
recent review on clinical evidence for OTC products for relief 
of hot flashes in menopausal women showed that the published 
literature is conflicting regarding efficacy.38 
Haimov-Kochman et al.39 examined the long-term safety 
and herb-drug interactions of commonly used herbal therapy 
such as soy, black cohosh, ginseng and vitamin E reported in 
the literature. The authors found that even carefully designed 
studies on herbal treatments for vasomotor menopausal 
symptoms did not specifically address safety issues.  
 
Anxious and Depressive Patients 
Anxiety disorders are among the most common psychiatric 
disorders that affect all age groups of the general population. 
The preferred treatment is with antidepressant or anti-anxiety 
drugs that have adverse effects, such as sedation, impaired 
cognition, ataxia, aggression, sexual dysfunction, tolerance 
and dependence. Several studies have suggested that self-
medication with herbals is largely distributed among anxious 
and depressive patients.40 Herbal remedies, including kava 
(Piper methysticum), are effective treatments, at least in mild 
to moderate cases of anxiety.41 Kava is a social and ceremonial 
herb from the South Pacific. It is available in the west as OTC 
preparation. The biologically active kavalactones reveal 
sedative, anxiolytic, antistress, analgesic, local anaesthetic, 
anticonvulsant and neuroprotective properties. The 
pharmacological properties of kava are postulated to include 
blockade of voltage-gated sodium ion channels, enhanced 
ligand binding to gamma-aminobutyric acid (GABA) type A 
receptors, diminished excitatory neurotransmitter release due 
to calcium ion channel blockade, reduced neuronal reuptake of 
noradrenaline (norepinephrine), reversible inhibition of 
monoamine oxidase B and suppression of the synthesis of 
eicosanoid thromboxane A(2), which antagonises GABA(A) 
receptor function. Kava and kavalactones are effective in the 
treatment of anxiety due to various medical conditions.42 Until 
recently, the adverse effects attributed to kava use were 
considered as mild or negligible, except for the occurrence of 
skin lesions. Kava dermopathy occurs only with prolonged use 
of large amounts of kava and is reversible on reduced intake or 
cessation. Rare cases of interactions have occurred with 
pharmaceutical drugs that share mechanisms of action with 
kavalactones. Cases of severe liver toxicity associated with 
kava intake have been reported. However, a direct causal 
relationship with kava use has been difficult to establish in the 
majority of cases.  
 
Patients Suffering from Insomnia 
Insomnia is a common condition resulting in significant 
clinical and economic consequences.43 Meolie et al.44 
evaluated the safety and efficacy of non-prescription therapies 
used for insomnia. Therapies include passion flower, valerian, 
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Jamaican dogwood, hops, California poppy, chamomile, 
lemon balm, St. John's wort, kava kava, wild lettuce, scullcap, 
Patrinia root, first-generation histamine-1-receptor antagonists, 
and others. Although randomized, placebo-controlled studies 
were available for some drugs, rigorous scientific data 
supporting a beneficial effect are not found for the majority of 
herbal supplements used for treating insomnia symptoms. 
There are significant potential risks associated with the use of 
Jamaican dogwood, kava kava, alcohol, and I-tryptophan. 
 
Dermatological Patients 
Herbal preparations and isolated phytochemicals are 
increasingly used for dermatological ailments.45,46 In acne 
therapy, tea tree oil, Mahonia, and Saccharomyces may 
become standard treatments. Mahonia, Hypericum, 
Glycyrrhiza and some traditional Chinese medicines appear 
promising for atopic dermatitis. Some plant-derived substances 
such as dithranol and 8-methoxypsoralen (in combination with 
UV-A irradiation) are already accepted as standard treatments 
in psoriasis. Mahonia and Capsicum (capsaicin) are also 
promising candidates. Oral administration and topical 
application of antioxidant plant extracts (green and black tea, 
carotenoids, coffee, and many flavonoids from fruits and 
vegetables) can protect skin from UV-induced erythema, early 
aging, and irradiation-induced cancer. Hair loss and vitiligo 
are also traditional fields of application for herbal products. 
 
Ulceration 
Aphthous ulceration is a disease of the intra-oral mucosa 
that is often self-managed by OTC medication. However, there 
are no randomized controlled studies to demonstrate OTC 
preparations do more than manage symptoms.47 Exceptions are 
OTC cyanoacrylate products and CankerMelts GX patches, 
which contain Glycyrrhiza glabra (licorice) extracts. 
CankerMelts alters the course of the condition by reducing 
lesion duration, size, and pain. It may be as effective as the 




The use of herbs has been advocated as alternative treatment 
for human immunodeficiency virus-related illness. Kassler et 
al.48 interviewed 114 randomly selected patients. Twenty-five 
participants (22%) reported using one or more herbal products 
in the past three months. Of those taking herbs, six (24%) were 
unable to identify the herb that they had used. Twelve patients 
(48%) reported taking herbs for longer than 90 days. Of those 
taking herbs, five (20%) stated that their primary medical 
provider was unaware of their herb use, and four (16%) were 
involved in clinical drug trials while using herbs. Adverse 
effects include dermatitis, nausea, vomiting, diarrhea, 
thrombocytopenia, coagulopathies, altered mental status, 
hepatotoxicity, and electrolyte disturbances. 
 
Influenza Patients 
Influenza infection is still a leading cause of morbidity and 
mortality, accounting for 20–25 million doctor visits and 
36,000 deaths per year in the U.S.A.  Conventional therapies 
for colds and flu focus primarily on temporary symptom relief 
and include OTC antipyretics, anti-inflammatories, and 
decongestants. Treatment for influenza also includes 
prescription antiviral agents and vaccines for prevention. Some 
herbal drugs (Echinacea spp., Sambucus nigra, larch 
arabinogalactan, Astragalus membranaceous, Baptisia 
tinctoria, Allium sativa, Panax quinquefolium, Eleuthero-
coccus senticosus, Andrographis paniculata, olive leaf extract, 
and Isatis tinctoria) and nutritional supplements (vitamins A 
and C, zinc, high lactoferrin whey protein, N-acetylcysteine, 
and DHEA) may support prevention and treatment.49 
 
Patients with Eating Disorder 
The rhizome and roots of the South-American plant, Ipe-
cacuanha (ipecac, Cephaelis ipecacuanha or C. acuminata) is 
used as emetic and expectorant. The use of gastric emptying 
techniques, including ipecac-induced emesis, in the 
management of poisoned patients has declined significantly in 
recent years. Ipecac syrup was administered to patients prior to 
referral to the emergency department in attempts to start the 
gastric emptying process as early as possible. Ipecac abuse 
occurs predominantly among adolescent and young adult 
females who are either experimenting with purging or have an 
eating disorder.50 Studies to determine the effectiveness of 
ipecac syrup demonstrate that it induces vomiting in a high 
percentage of people and that it decreases the gastrointestinal 
absorption of ingested substances. However, the effectiveness 
of ipecac syrup in affecting patient outcome has not been 
studied in adequate clinical trials. Its effectiveness in 
preventing drug absorption has only been documented for a 
limited number of substances.51 
Psychiatric co-morbidity is common. Death can occur and is 
usually of cardiac origin. Morbidity includes myocarditis with 
arrhythmias, myositis, gastroesophageal conditions, diarrhea, 
and metabolic abnormalities (alkalosis, hypokalemia, 
dehydration). The injuries are reversible upon cessation of 
ipecac use. Emetine is an active alkaloid in ipecac, which may 
account for these effects. 
 
2 Risks Associated with Herbal Self-Medication 
Missing Quality Control 
The increase in popularity of herbal products has also 
brought concerns and fears on the professionalism of 
practitioners, and quality, efficacy and safety of their treatment 
methods and remedies available on the market.52 Herbal 
toxicity and adverse effects are well documented in classical 
Chinese medical textbooks. During the past decade severe and 
sometimes even life-threatening intoxications after intake of 
OTC herbal products became aware to the public media. 
Toxicity associated with herbal OTC therapy can derive from53: 
(1) Correctly identified medicinal plants with unknown 
toxicity. 
(2) Incorrectly identified medicinal plants with toxic activity. 
Botanical misidentification or mislabeling of plant material 
can play a role for toxic reactions in humans. 
(3) Contamination of herbs with pesticides, heavy metals, 
and radioactivity taken up from the soil as well as organic 
solvents and microbial contamination due to unprofessional 
processing of harvested herbs. 
(4) Substitution or adulteration with other herb or chemical 
drugs may deliberately occur for economic reasons, if a faked 
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herb is cheaper than the original replaced one or for increasing 
the activity of an herbal mixture by adding a drug with well-
known activity for the same indication. 
An important role to prevent toxicities associated with low 
quality herbal products plays the establishment of international 
quality control standards54: 
- The correct identification of medicinal plants is of 
utmost importance, since wrongly identified plants may 
contain poisonous ingredients. 
- Standardization of production of herbal prescriptions 
by international quality guidelines such as Good Sourcing 
Practice (GSP) to guarantee authentication of medicinal plants, 
Good Agricultural Practice (GAP), Good Laboratory Practice 
(GLP), Good Manufacturing Practice (GMP), and Good 
Clinical Trial Practice (GCTP). 
- Processing procedures of herbal products have to be 
standardized. 
- Chromatographic fingerprinting analysis can disclose 
the detectable ingredients composition and concentration 
distribution. 
- Quality control has not only the task to ensure proper 
composition of herbal prescriptions but also to avoid 
contamination with mycotoxins, pesticides, heavy metals, or 
other chemical toxins. Furthermore, faked herbal prescriptions 
with adulteration of drugs from Western medicine, e.g., with 
glucocorticoids, have to be banned. 
- Strengthening research on the physiological and 
pharmacological activity of herbal remedies. 
 
Toxicity 
Hepatotoxic effects have been reported for more than 300 
plant species, including Heliotropium, Crotalaria, Senecio and 
Symphytum.55–57 In Africa or Central America, intoxication is 
sometimes endemic, since these plants are often used for 
making tea. In Western countries, cases of herb-induced 
hepatitis have been observed after use of preparations 
containing Symphytum or Chinese herbs. The pyrrolizidine 
alkaloid-containing germander (Teucrium chamaedrys) was 
used for weight loss. Atractylis gummifera is used for 
medicinal purposes or for chewing gum, but is hepatotoxic.  
Fatal liver accidents may occur after ingesting Callilepis 
laureola, a herb used by the Zoulous in Natal for medicinal 
purposes. These examples emphasize the importance of 
remembering that herbal medicine is not harmless.  
Ulbricht et al.58 identified more than 80 herbs or herbal 
products (including plants, fungi, algae, and common 
constituents) showing clinical interactions with prescription 
and OTC drugs. Drugs with anticoagulant/antiplatelet activity 
(e.g. warfarin, aspirin) were frequently implicated in herb-drug 
interactions. Because many herbs have demonstrated adverse 
effects on the liver, the potential for interaction with 
hepatotoxic agents (such as acetaminophen) is also 
significant.59 
Herbal medicines are metabolized by phase I/II enzymes, 
including cytochrome P450 enzymes (CYP) and 
glucuronosyltransferases (UGTs) and translocated by phase III 
transporters such as P-glycoprotein (Pgp), increasing the 
likelihood of hepatotoxicity.60 Examples include include black 
cohosh, Echinacea, garlic, piperine, ginseng, ginger, Gingko 
biloba, green tea, kava, milk thistle, St. John's wort, and others. 
It is common for individuals with renal insufficiency to 
supplement their prescriptive treatment with non-prescription 
medications, herbal medicines, nutritional supplements and 
vitamins. Renal insufficiency may put individuals at an even 
higher risk for adverse events.61,62 
 
Herb-Drug Interactions 
Based on available clinical observations, some commonly 
used herbs have been demonstrated to interact with Western 
therapy.63 Herbal medicines can cause abnormal test results 
and confusion in proper diagnosis. Herbal medicines can alter 
test results by direct interference with certain immunoassays. 
Drug-herb interactions can result in unexpected concentrations 
of therapeutic drugs.64,65 The frequency of interactions must 
not be underestimated. Yoon and Schaffer66 identified drug-
drug interactions (DDIs) using a Web-based pharmaceutical 
program. At least one moderate or high-risk DDI was 
identified in 74% of participants, with 136 total DDIs 
identified. Fifty-two percent (71) of total DDIs were between 
prescribed and OTC or herbal products with 63% (45) of these 
involving nonsteroidal antiinflammatory drugs. 
Bush et al.67 performed a review of the patient's chart for 
evidence of an observed adverse herb-drug interaction. Out of 
804 patients surveyed, 122 (15%) used herbal medicines. 
Eighty-five potential adverse herb-drug interactions were 
found in 49 patients (40% of herbal medicine users). Twelve 
possible adverse herb-drug interactions in 8 patients (7% of 
herbal medicine users) were observed. In all 12 cases, the 
severity scores were rated as mild, including 8 cases of 
hypoglycemia in diabetics taking nopal (prickly pear cactus).  
Using a matrix of 165 possible drug-herb interaction pairs 
(15 therapeutic drug classes by 11 herbal products), Brazier 
and Levine68 identified 51 (31%) interactions. Twenty-two of 
these 51 drug-herb pairs (43%) were supported by randomized 
clinical trials, case-control studies, cohort studies, case series, 
or case studies. The remaining interaction pairs reflected 
theoretic reasoning in the absence of clinical data. Most 
interactions were pharmacokinetic, most of which affected 
cytochrome p450 enzymes. 
While cytochrome P450-mediated herb-drug interactions 
have been extensively characterized, the effects of herbal 
extracts and constituents on UDP-glucuronosyl transferase 
(UGT) enzymes have been less studied. Mohamed and Frye69 
evaluated current evidence on the glucuronidation of 
phytochemicals and the potential for UGT-mediated herb-drug 
interactions with top-selling herbal supplements in U.S.A. and 
Europe. In vitro and animal studies indicate that cranberry, 
Ginkgo biloba, grape seed, green tea, hawthorn, milk thistle, 
noni, soy, St. John's wort, and valerian are rich in 
phytochemicals that modulate UGT enzymes. However, the in 
vivo consequences of these interactions are not well 
understood as yet. 
 
3 Perspectives for a ‘Take Actions’ Plan 
Development of Educational Programs and Databases 
Self-administration of medication suggests that individuals 
are functionally and cognitively competent to manage their 
health care. However, this is not always the case. Therefore, 
physicians, pharmacists, nurses, midwifes, and other health 
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care professionals have a critical responsibility assessing the 
self-care ability of their patients.70,71 Databases are available 
for pharmacists with information on action, side effects and 
toxicities as well as herb-drug interactions. A well known 
database is the DMDI-ABDA database of the German Institute 
for Medical Documentation and Information (http://www. 
dimdi.de/static/de/amg/abda/index.htm). Some health care 
professionals working with patients,  may find themselves 
confronted with questions about herbal  remedies, yet may feel 
unable to answer them or be unsure where to find information. 
However, with the generally increased use of complementary 
therapies, efforts are necessary to facilitate health 
professionals to offer accurate, comprehensive and evidence-
based information to patients.72 Physicians should routinely 
ask patients about their use of dietary supplements when 
starting or stopping a prescription drug, or if unexpected 
reactions occur. Patient and physician education, and regular 
medication monitoring are essential to prevent polypharmacy. 
Since there are still scant guidelines about the assessment of 
safe self-administration of conventional and herbal medication, 
novel initiatives for improvement are required.73 
 
Guidelines and Phytovigilance 
There is a need for established guidelines regarding 
discontinuation of selected natural products prior to surgery 
and further education is needed concerning the perioperative 
implications of natural products.20 Good communication with 
surgical patients, including the administration of a presurgical 
questionnaire to help identify any use of herbal medications, is 
very important. 
The absence of precise prescribing guidelines, and the risk 
of self-prescribed medication justify the introduction of 
'phyto-vigilance'. Self-medication-induced morbidity might 
be prevented by the documentation of medicines in the 
medical record and review of the medical record before new 
medications are prescribed. The relevance of this topic is 
illustrated in a survey of Jaski et al.. 74 Documentation and 
review by primary care physicians of patients using 
prescription drugs, OTC products, nutritional supplements, 
and herbal treatments were surveyed among 1802 internists 
and family practitioners from the American Medical 
Association Physician Masterfile. Almost all of the 655 
responders reported reviewing prescription medications before 
prescribing a new therapy (99.8%), but only 86% reported 
reviewing OTCs at the same time. Fewer than half of 
physicians reported reviewing nutritional supplements or 
herbal treatments before prescribing a new therapy. Since the 
response rate of physicians was low, the authors concluded 
that their results probably overestimated actual rates of 
documentation and review. Review and documentation of 
nonprescription substances are uncommon in primary care 
practice. 
Adverse drug interactions are among the leading causes of 
death in hospitalized patients. In children and older adults 
undetected food/herb-drug interactions may lead to serious 
morbidity and mortality and be misdiagnosed as chronic 
disease progression.75 Recent recognition of the effects of 
certain foods on many drugs metabolized by CYP450 families 
or drugs susceptible to chelation and adsorption have increased 
awareness for prevention of food-drug interactions. Self-
medications with non-prescription herbal remedies, nutritional 
supplements, and genetic polymorphisms in drug metabolism 
enzymes increase the need to consider food/herb-drug 
interactions. Prevention of adverse events from herb-drug 
interactions requires clinical monitoring in high-risk regimens 
and populations. The nutritional status has an important impact 
on the quality of life as well as appropriate responses to drug 
therapy. Both diet-drug histories and counseling are needed.75 
Faced with the extensive distribution of many herbal 
preparations and the risk of self-medication, consumers, 
clinicians, pharmacists, and health care professionals should 
be vigilant with potentially toxic herbal OTC products. 
Personal use of dietary supplements and herbal OTC products 
correlated with a twofold increase in the likelihood that a 
pharmacist would recommend a dietary supplement to a 
patient.76 This indicates that there is a need among pharmacists 
for dietary supplements information to be included in 
pharmacy computer systems, specifically to check for 
interactions against the patient's drug profile. Although 
practitioners as well as journal articles are preferred 
information sources, the internet and the personal talk with the 
pharmacist are also important sources. Pharmacists should 
provide competent information of non-prescription herbal 
products and dietary supplements. It is essential for 
pharmacists to counsel patients and the general public on the 
benefits and risks associated with supplement use.77 
 
Information Centers 
Information centers for consumers and general practitioners 
shall meet the strong demand for counseling and providing 
high-quality, evidence-based information on exposures of risk 
groups. An illustrative example for such an information center 
is “MotherSafe”, which was established at the Royal Hospital 
for Women (Randwick NSW, Australia).78 MotherSafe is an 
information service on teratogenic exposures during pregnancy 
and lactation. 
To obtain a rational basis about the needs for such 
information centers, the interests of custumors have to be 
known. A retrospective review of 1087 queries submitted 
online to an “Ask your Pharmacist” (AYP) service has been 
published by Assemi et al..79 The authors described consumer 
demographics regarding gender, age, patient relationship to 
consumer, allergies, medical conditions, products, and 
evaluated the types of submitted questions. Consumers of all 
ages used the AYP services for both acute and chronic 
conditions. Most consumers asked questions related to their 
own health or medications. Consumers were more likely to ask 
questions related to prescription and OTC medications than to 
botanical and dietary supplements. Consumers were primarily 
interested in drug efficacy and adverse effects. 
 
Clinical Trials 
Many data available on the effects of natural medicines is 
only anecdotal. Numerous case reports and information on 
compassionate use of herbal products might indicate that 
herbal products are effective, but current quality control 
standards are highly variable. In order to ensure quality control 
and standardization of products, preparations manufactured by 
companies that adhere to good practice standards (GSP, GAP, 
GMP, etc.) are advisable. 
There is a lack of controlled clinical trials and the incidence 
of adverse effects is not clarified. Many plant products do not 
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seem to lead to toxic effects in everyone taking them, and they 
commonly lack a strict dose-dependency.56 Herbal products 
should fulfill the criteria of evidence-based medicine to gain 
full recognition in Western medicine. Therefore, placebo-
controlled, double blind and randomized clinical trials are 
needed to provide convincing evidence on safety and efficacy 
of herbal products. Current clinical trial protocols frequently 
do not reflect the "typical" general elderly population are 
needed.14 
 
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribu-
tion, and reproduction in any medium, provided the original author(s) 
and source are credited. 
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